Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 7.71
(-2.28%)
SEK 7.71
(-2.28%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 217.03 Million SEK | 5.46% |
| 2023 | 205.8 Million SEK | -12.99% |
| 2022 | 236.52 Million SEK | 17.42% |
| 2021 | 201.43 Million SEK | 124.41% |
| 2020 | 89.76 Million SEK | 20.97% |
| 2019 | 74.2 Million SEK | 34.96% |
| 2018 | 54.98 Million SEK | -44.26% |
| 2017 | 98.64 Million SEK | 161.12% |
| 2016 | 37.77 Million SEK | -19.01% |
| 2015 | 46.64 Million SEK | -8.58% |
| 2014 | 51.02 Million SEK | -24.76% |
| 2013 | 67.81 Million SEK | -83.92% |
| 2012 | 421.73 Million SEK | -18.83% |
| 2011 | 519.6 Million SEK | -8.71% |
| 2010 | 569.19 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 248.19 Million SEK | 9.59% |
| 2024 Q4 | 217.03 Million SEK | -12.55% |
| 2024 Q1 | 263.6 Million SEK | 28.08% |
| 2024 Q2 | 226.47 Million SEK | -14.09% |
| 2023 Q1 | 201.8 Million SEK | -14.68% |
| 2023 Q4 | 205.8 Million SEK | 31.47% |
| 2023 Q3 | 156.54 Million SEK | -10.91% |
| 2023 FY | 205.8 Million SEK | -12.99% |
| 2023 Q2 | 175.7 Million SEK | -12.93% |
| 2022 Q2 | 322.16 Million SEK | -3.01% |
| 2022 Q4 | 236.52 Million SEK | -18.83% |
| 2022 Q1 | 332.16 Million SEK | 64.9% |
| 2022 FY | 236.52 Million SEK | 17.42% |
| 2022 Q3 | 291.41 Million SEK | -9.55% |
| 2021 Q3 | 238.56 Million SEK | 17.28% |
| 2021 Q2 | 203.41 Million SEK | 6.51% |
| 2021 Q4 | 201.43 Million SEK | -15.56% |
| 2021 Q1 | 190.97 Million SEK | 112.75% |
| 2021 FY | 201.43 Million SEK | 124.41% |
| 2020 Q1 | 66.28 Million SEK | -10.67% |
| 2020 FY | 89.76 Million SEK | 20.97% |
| 2020 Q2 | 102.49 Million SEK | 54.63% |
| 2020 Q3 | 95.29 Million SEK | -7.03% |
| 2020 Q4 | 89.76 Million SEK | -5.8% |
| 2019 Q2 | 93.02 Million SEK | 97.99% |
| 2019 FY | 74.2 Million SEK | 34.96% |
| 2019 Q4 | 74.2 Million SEK | -14.32% |
| 2019 Q3 | 86.6 Million SEK | -6.9% |
| 2019 Q1 | 46.98 Million SEK | -14.55% |
| 2018 Q2 | 73.91 Million SEK | -14.89% |
| 2018 Q4 | 54.98 Million SEK | -15.11% |
| 2018 Q3 | 64.76 Million SEK | -12.37% |
| 2018 Q1 | 86.84 Million SEK | -11.97% |
| 2018 FY | 54.98 Million SEK | -44.26% |
| 2017 Q3 | 19.77 Million SEK | -26.52% |
| 2017 Q2 | 26.91 Million SEK | -19.8% |
| 2017 Q4 | 98.64 Million SEK | 398.85% |
| 2017 FY | 98.64 Million SEK | 161.12% |
| 2017 Q1 | 33.55 Million SEK | -11.18% |
| 2016 Q1 | 41.89 Million SEK | -10.19% |
| 2016 FY | 37.77 Million SEK | -19.01% |
| 2016 Q3 | 41.61 Million SEK | 9.89% |
| 2016 Q4 | 37.77 Million SEK | -9.21% |
| 2016 Q2 | 37.86 Million SEK | -9.61% |
| 2015 Q1 | 44.86 Million SEK | -12.07% |
| 2015 FY | 46.64 Million SEK | -8.58% |
| 2015 Q3 | 51.43 Million SEK | 25.27% |
| 2015 Q4 | 46.64 Million SEK | -9.31% |
| 2015 Q2 | 41.05 Million SEK | -8.49% |
| 2014 Q2 | 59.04 Million SEK | -7.3% |
| 2014 Q1 | 63.69 Million SEK | -6.08% |
| 2014 Q4 | 51.02 Million SEK | -6.3% |
| 2014 FY | 51.02 Million SEK | -24.76% |
| 2014 Q3 | 54.45 Million SEK | -7.77% |
| 2013 Q3 | 51.42 Million SEK | 0.0% |
| 2013 Q4 | 67.81 Million SEK | 31.89% |
| 2013 FY | 67.81 Million SEK | -83.92% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q1 | 482.83 Million SEK | -7.08% |
| 2012 FY | 421.73 Million SEK | -18.83% |
| 2012 Q3 | 449.74 Million SEK | -3.55% |
| 2012 Q2 | 466.29 Million SEK | -3.43% |
| 2012 Q4 | 421.73 Million SEK | -6.23% |
| 2011 Q2 | 554.29 Million SEK | 0.0% |
| 2011 FY | 519.6 Million SEK | -8.71% |
| 2011 Q3 | 525.26 Million SEK | -5.24% |
| 2011 Q4 | 519.6 Million SEK | -1.08% |
| 2010 FY | 569.19 Million SEK | 0.0% |
| 2010 Q4 | 569.19 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | -76.183% |
| Amniotics AB (publ) | 26.08 Million SEK | -732.01% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -3471.466% |
| BioArctic AB (publ) | 1.18 Billion SEK | 81.701% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 88.58% |
| Saniona AB (publ) | 64.14 Million SEK | -238.366% |
| Simris Alg AB (publ) | 174.55 Million SEK | -24.34% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 56.264% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1359.668% |
| NextCell Pharma AB | 81.28 Million SEK | -166.999% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -619.311% |
| AcouSort AB (publ) | 34.51 Million SEK | -528.859% |
| Active Biotech AB (publ) | 44 Million SEK | -393.268% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -83.232% |
| Camurus AB (publ) | 1.9 Billion SEK | 88.624% |
| Cantargia AB (publ) | 223.71 Million SEK | 2.983% |
| Genovis AB (publ.) | 288.85 Million SEK | 24.863% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -154.659% |
| Mendus AB (publ) | 755.95 Million SEK | 71.289% |
| Kancera AB (publ) | 65.64 Million SEK | -230.634% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 82.753% |
| LIDDS AB (publ) | 17.65 Million SEK | -1129.329% |
| Lipum AB (publ) | 12.11 Million SEK | -1692.221% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -545.908% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 22.137% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -982.97% |
| OncoZenge AB (publ) | 20.34 Million SEK | -967.05% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 66.789% |
| Xintela AB (publ) | 18.39 Million SEK | -1079.875% |
| Ziccum AB (publ) | 14.97 Million SEK | -1349.626% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -54.369% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 71.639% |
| CombiGene AB (publ) | 120.61 Million SEK | -79.947% |
| Intervacc AB (publ) | 259.61 Million SEK | 16.399% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -247.946% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -417.262% |
| Corline Biomedical AB | 100.1 Million SEK | -116.81% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -22.537% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -249.205% |
| Aptahem AB (publ) | 63.02 Million SEK | -244.368% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 38.225% |
| Fluicell AB (publ) | 9.34 Million SEK | -2223.747% |
| Biovica International AB (publ) | 131.4 Million SEK | -65.163% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -309.622% |
| Abliva AB (publ) | 87.49 Million SEK | -148.046% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 71.45% |
| 2cureX AB (publ) | 16.62 Million SEK | -1205.492% |
| I-Tech AB | 152.44 Million SEK | -42.373% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 78.681% |
| Cyxone AB (publ) | 43.65 Million SEK | -397.166% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -175.807% |
| Biosergen AB | 7.2 Million SEK | -2913.998% |
| Nanologica AB (publ) | 77.42 Million SEK | -180.306% |
| SynAct Pharma AB | 228.01 Million SEK | 4.816% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -710.963% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 84.499% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -900.043% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 8.952% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -2466.978% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -149.263% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -661.323% |